Morgan Stanley analyst Matthew Harrison maintains Innoviva (NASDAQ:INVA) with a Underweight and lowers the price target from $13 to $10.
- Headlines
- Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $10
Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $10
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
02:16
The Israeli military stated that they made a request to the Lebanese army before the attack, and that the launcher was only targeted after the Lebanese military did not address the request.
02:16
On Thursday (January 2), the scale of the Federal Reserve's overnight reverse repurchase agreement (RRP) was 239.858 billion USD, compared to 473.46 billion USD on the previous trading day.
02:15
Several more brokerages have been approved to participate in the swap convenience business.
Sinolink-4.47%